The relationship between metoclopramide and hypothalamus-pituitary-thyroid axis and it's clinical application.
- Author:
Qingjing DAI
1
;
Anren KUANG
Author Information
1. Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Dopamine Antagonists;
pharmacology;
Humans;
Hyperthyroidism;
blood;
drug therapy;
Hypothalamo-Hypophyseal System;
drug effects;
physiology;
Hypothyroidism;
blood;
drug therapy;
Metoclopramide;
chemistry;
pharmacology;
Thyroid Gland;
drug effects;
physiology;
Thyroid Hormones;
blood;
Thyrotropin;
blood
- From:
Journal of Biomedical Engineering
2004;21(1):164-168
- CountryChina
- Language:Chinese
-
Abstract:
TSH secretion is controlled by the stimulatory action of hypothalamic TRH and the inhibition via central dopaminergic and somatostatinergic mechanisms as well as by a hypothalamic inhibitory action of thyroid hormones. Metoclopramide is DA2 receptor blockade which can accelerate to elevate the concentration of serum TSH in hypothyroidism, which is accompanied by a progressive loss of dopaminergic tone as demonstrated by a progressive increase in prolaction serum levels, especially in patients with differentiated thyroid carcinoma(DTC). So the period of L-thyroxine withdrawal is contracted and the symptoms of hypothyroidism is released. It's important to monitor and treat DTC patients with radioactive iodide.
